Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Quality Metrics Initiative Continues Moving Forward … Quietly

Executive Summary

Despite few public announcements and industry concerns, FDA's Office of Pharmaceutical Quality director says program is not dead.

You may also be interested in...



US FDA Guidance Production May Be Slowed By New OMB Review Requirement

White House says all guidances, as well as proposed rules, must be submitted to OMB for a determination whether they are major or minor.

Drug Shortages: Is "Buy American" One Solution?

Moving more manufacturing to the US could help increase supply chain reliability, which could prevent or blunt shortages, an industry representative argues.

Drug Shortages: Is "Buy American" One Solution?

Moving more manufacturing to the US could help increase supply chain reliability, which could prevent or blunt shortages, an industry representative argues.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel